Didemnin B

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameDidemnin B
Drug Alias NameNorDNSC-325319Didemnin B
ClassificationNatural product/ExtractSmall molecules
Mechanisms of ActionProtein biosynthesis inhibitorsDNA synthesis inhibitors
TargetsNot applicable
Therapy Area/IndicationsBrain NeoplasmsLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsBrain NeoplasmsLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksWikipedia